Asian Journal of Orthopaedic Research



High Dose-Short Duration Therapy of Cholecalciferol as a New Therapeutic Approach in the Treatment of Chronic Low Back Pain Associated with Vitamin D Deficiency

Khan Hasnat Iqbal ^{a++*}, Harsh Chaturvedi ^{a++}, Sumangal Ghatak ^{a++} and Jyothsna Kuralla ^{a++}

^a Medical and Scientific Affairs, Pulse Pharmaceuticals, Hyderabad, India.

Authors' contributions

This work was carried out in collaboration among all authors. All authors read and approved the final manuscript.

Article Information

DOI: https://doi.org/10.9734/ajorr/2025/v8i1204

Open Peer Review History:

This journal follows the Advanced Open Peer Review policy. Identity of the Reviewers, Editor(s) and additional Reviewers, peer review comments, different versions of the manuscript, comments of the editors, etc are available here: https://www.sdiarticle5.com/review-history/128368

Review Article

Received: 28/10/2024 Accepted: 30/12/2024 Published: 03/01/2025

ABSTRACT

Chronic low back pain (CLBP) is a significant health issue, often linked to widespread vitamin D deficiency, particularly in Indian populations where prevalence exceeds 70%. This review evaluates the efficacy and safety of Oral Cholecalciferol Nano-Syrup therapy of High-Dose, Short-Duration (60,000 IU/day for 10 days) versus Conventional Weekly Vitamin D supplementation (60,000 IU/week for 12 Week) for the treatment of Vitamin D deficiency associated with Chronic Low Back

Cite as: Iqbal, Khan Hasnat, Harsh Chaturvedi, Sumangal Ghatak, and Jyothsna Kuralla. 2025. "High Dose-Short Duration Therapy of Cholecalciferol As a New Therapeutic Approach in the Treatment of Chronic Low Back Pain Associated With Vitamin D Deficiency". Asian Journal of Orthopaedic Research 8 (1):1-6. https://doi.org/10.9734/ajorr/2025/v8i1204.



⁺⁺Medical Affairs;

^{*}Corresponding author: Email: medicalaffairs3@pulsepharma.net;

Pain. While weekly regimens achieve vitamin D sufficiency rates of 44–68%, the High-Dose, Short-Duration therapy of Nano-syrup therapy consistently attains 100% sufficiency within 10 days, alongside marked improvements in Visual Analog Scale (VAS) and Modified Oswestry Disability Questionnaire (MODQ) scores, with reductions of up to 75% and 40%, respectively. The High-Dose, Short-Duration approach also demonstrated a favorable safety profile, with no serious adverse events reported. These findings suggest that high-dose, short-duration vitamin D therapy offers a more effective and efficient alternative for managing vitamin D deficiency and associated CLBP, highlighting its potential for broader clinical application.

Keywords: Chronic low back pain; vitamin D deficiency; nano-syrup; high-dose therapy; cholecalciferol.

1. INTRODUCTION

Chronic low back pain (CLBP), is defined as the pain or, localized below the costal margins and above the inferior gluteal folds, which may be accompanied by sciatica and persist for ≥ 12 weeks (Hayden et al., 2021). Low back pain is one of the most prevalent orthopaedic complaints that may result in significant loss of functionality of individuals across all age groups (Alfalogy et al., 2023). In addition to physical impairment, bears lower back pain а tremendous psychological influence such that anxiety and despair are prevalent among patients with low back pain overall affecting their quality of life (Alfalogy et al., 2023; Jiang et al., 2022).

The estimated worldwide lifetime prevalence of low back pain varies from 50% to 84% (Fatoye et al., 2019; Badley et al., 2010). The occurrence of low back pain in India is also alarming with nearly 60% of the people in India have suffered from low back pain at some time during their lifespan (Koley & Sandhu, 2009). Few studies have also found that individuals of lower economic status had a higher prevalence of CLBP than those of higher economic status (Alfalogy et al., 2023).

A vitamin that is known to play a very important part in maintaining good health is Vitamin D, which is a fat-soluble vitamin (Rebelos et al., 2023). Various names like sunshine vitamin and antirachitic factor have been given to this vitamin (V N et al., 2024). Vitamin D's distinctiveness lies in the fact that it is synthesized in our skin when we are exposed to sunlight. Ample sunlight exposure and food items like oily fish (Salmon) are the main sources of vitamin D (V N et al., 2024).

Vitamin D measured as a 25(OH) D level of >30 ng/ml is generally considered "Sufficient", whereas a 25(OH) D level of 20-29.9 ng/ml is "Insufficient", and a 25(OH) D level of <20 ng/ml

as "Deficient" (Holick et al., 2011). Serum 25(OH) D level of >150 ng/ml is generally considered a "Toxic level" (Holick et al., 2011).

The results from various meta-analyses indicate that vitamin D deficiency was more prevalent among people with LBP than in those who did not experience any back pain (V N et al., 2024).

Similarly, an extensive meta-analysis conducted by Zadro et al. concentrating on the relationship between Vitamin D and LBP, likewise uncovered a positive connection between LBP and lack of Vitamin D (V N et al., 2024).

In a review observational examination done by Gokcek and Kaydu, it was found that decreased degrees of Vitamin D were related to increased severity of LBP (V N et al., 2024).

Also, in Indian patients with Chronic Low back pain, the Prevalence of Vitamin D deficiency was found to be 70-90% (V N et al., 2024; Gokcek & Kaydu, 2018; Khanna et al., 2020).

Vitamin D is a proven anabolic hormone that promotes skeletal muscle and bone health as well as maintains immune function, with its inherent anti-inflammatory effects (Bai et al., 2024).

Thus, Vitamin D deficiency is an overtly underestimated, preventable and correctable etiological factor for CLBP (Bai et al., 2024).

Other than problems with the skeletal system, other health issues like increased risk of diabetes mellitus type 2, cancer, and cardiovascular diseases are associated with Vitamin D deficiency (Bai et al., 2024).

2. VITAMIN D TREATMENT REGIME

Vitamin D treatment regime is given in Table 1 as per Indian Clinicians (Kalra et al., 2023):

Individuals	Dosage	Duration
Asymptomatic	800-2000 IU/Day	-
Symptomatic Vitamin D insufficient	60,000 IU/Week	Initiation dose of 8 weeks
		If unsatisfactory, once a week for 8 weeks
		Maintenance dose of once a month
Symptomatic Vitamin D deficient	60,000IU/Week	Initiation dose of 12 weeks
		If unsatisfactory, once a week for 8 weeks
		Maintenance dose of once a month

Table 1. Treatment regime for Vitamin D deficiency/insufficiency

3. PROBLEMS WITH CURRENT WEEKLY SUPPLEMENTATION OF VITAMIN D FOR THE TREATMENT OF VITAMIN D DEFICIENCY

Even after weekly supplementation at the end of the study period, the group of participants have not been able to reach the sufficiency level (>30 ng/ml).

Few Indian studies indicate the problem:

- A study done in Srinagar in 2015 by Mohammad Shafi Kuchay et.al., showed that Vitamin D supplementation of 60,000 IU for 4 weeks followed by 60,000 IU/ Month till 12 months, resulted in 68% of patients reaching sufficiency level with 42% patients remaining either in insufficiency/deficiency states (Kuchay et al., 2015).
- 2. Another study done by Goswami R et.al. in AIIMS Delhi, showed that weekly supplementation of 60.000 IU vitamin D for 8 weeks resulted in 56% of patients reaching sufficiency level while again 44% patients remained of either in insufficiency/deficiency states (Goswami et al., 2008).
- 3. A very interesting study by Dr C.V Harinarayan in Bangalore revealed that 60,000 IU/Week for 8 Weeks followed by a bimonthly dose of 60,000 IU for 12 weeks leads to **47% of patients** reaching sufficiency level while again **53% of patients** remained either in insufficiency/deficiency states (Harinarayan et al., 2023).

4. PROBLEMS WITH WEEKLY SUPPLEMENTATION OF VITAMIN D IN VITAMIN D DEFICIENCY ASSOCIATED WITH LOW BACK PAIN

1. Problem with the percentage of Patients reaching sufficiency:

A study by Ghai et al. study in 2017 in Chandigarh, showed that weekly

supplementation of 60,000 IU of Cholecalciferol for 8 weeks followed by a monthly dose of 60,000 IU of cholecalciferol was able to achieve sufficiency (25(OH)D level >29 ng/ml) in only **66%** of patients with **34%** patients remaining again in the deficiency/insufficiency state (Ghai et al., 2017).

Another trial by Kaunteya Krishna Das et al. in Madhya Pradesh showed that weekly supplementation of 60,000 IU of Cholecalciferol for 12 weeks achieved sufficiency in only around **44%** and **50%** of men and women respectively (Das et al., 2023).

5. ONE OF THE MAIN REASONS FOR THIS MAY BE THAT CONVENTIONAL VITAMIN D FORMULATIONS SUCH AS GRANULES AND CAPSULES HAVE BEEN USED IN THESE TRIALS

Introduction to Oral Cholecalciferol Nano Syrup: Oral Cholecalciferol Nano Syrup can be used to overcome the disadvantages of Granules and Capsules. Nano-syrup formulation has been proven to have better bioavailability than conventional Vitamin D3 formulations (Marwaha & Dabas, 2019; Nandgaye et al., 2023).

Introduction to High Dose-Short Duration therapy for Chronic Low Back Pain: Two Indian clinical trials highlight the efficacy and safety of Oral Cholecalciferol Nano-Vitamin D3 Oral Syrup as High-Dose-Short Duration Vitamin D therapy for Chronic Lower Back Pain.

- Lakkireddy M et.al. did a trial in 2019, in Hyderabad, which showed that Oral Nano Cholecalciferol Supplementation of 60,000 IU/day for 10 days resulted in 100% of patients achieving levels of 25(OH)D >30 ng/ml (Lakkireddy et al., 2019).
- Similar study done by K Santha Bai et al. in Andhra Pradesh in 2024, patients showed that Oral Nano-Vitamin D3 Cholecalciferol Supplementation of 60,000 IU/day for 10 days resulted in 100% of

patients achieving levels of 25(OH)D >30 ng/ml (Bai et al., 2024).

6. EFFICACY OF ORAL CHOLECALCIFEROL NANO-SYRUP AS HIGH DOSE-SHORT DURATION THERAPY IN CHRONIC LOW BACK PAIN

Lakkireddy et al. Showed that 10 days of continuous therapy of 60,000 IU Oral Nano

Syrup leads to an increase of 25(OH) D level to a mean of 96.75 ng/ml and a reduction of 75% in VAS Pain score and 40% in MODQ from baseline (Lakkireddy et al., 2019).

In addition, K Santha Bai et.al showed that 10 days of continuous therapy of 60,000 IU Oral Nano Syrup led to an increase of 25(OH) D level to a mean of 80.8 ng/ml and a reduction of 18% in VAS Pain Score and 27% in MODQ from baseline (Nandgaye et al., 2023).

Table 2. Efficacy of oral cholecalciferol nano-syrup as high dose-short duration therapy in
chronic low back pain

Author	Regime	Baseline Vitamin D	Final Vitamin D	%Reduction in MODQ	%Reduction in VAS
Lakkireddy M	Oral Nano Syrup 60,000 IU/day	16.69 ng/ml	96.75 ng/ml	39.65%	75%
K Santha Bai	Oral Nano Svrup 60.000 IU/dav	14.5 na/ml	80.8 na/ml	26.6%	17.5%
et al. (2024)	for 10 days				

7. SAFETY OF ORAL CHOLECALCIFEROL NANO-SYRUP AS HIGH DOSE-SHORT DURATION THERAPY IN CHRONIC LOW BACK PAIN

In both of the trials, no serious adverse event was reported (Bai et al., 2024; Lakkireddy et al., 2019).

Comparison of Efficacy in Weekly vs Daily Therapy of Vitamin D:

Author	Regime	Effects seen	Baseline Vitamin D	Final Vitamin D	%Reduction in MODQ	%Reduction in VAS
Ghai B et al. (2017)	60,000 IU Weekly for 8 weeks followed by 60,000 IU monthly for next 6 months	8 weeks	12.80 ng/ml	36.07 ng/ml	19%	55.55%
Kaunteya Krishna Das et al. (2023)	60,000 IU Weekly for 12 weeks	12 weeks	11.62 ng/ml	29.72 ng/ml	4.11%	22.29%
K Santha Bai et al. (2024)	60,000 IU/day for 10 days	12 weeks	14.5 ng/ml	80.8 ng/ml	26.6%	17.5%
Lakkireddy M et al. (2019)	60,000 IU/day for 10 days	21 st Day	16.69 ng/ml	96.75 ng/ml	39.65%	75%

Table 3. Comparison of weekly vs daily oral cholecalciferol supplementation in low back pain

8. CONCLUSION

Vitamin D deficiency is quite prevalent in chronic low back pain. Traditionally, Vitamin D supplementation is administered either as capsules or granules, typically on a weekly basis. However, research has shown that weekly supplementation may not achieve sufficiency in 100% of the population. The use of conventional Vitamin D formulations could be a contributing factor to this issue. In this context, oral cholecalciferol nano-syrup may offer a significant advantage. High-dose, short-duration therapy for chronic low back pain might be a more effective alternative to weekly supplementation, potentially improving efficacy without compromising safety.

DISCLAIMER (ARTIFICIAL INTELLIGENCE)

Author(s) hereby declare that NO generative AI technologies such as Large Language Models (ChatGPT, COPILOT, etc.) and text-to-image generators have been used during the writing or editing of this manuscript.

CONSENT AND ETHICAL APPROVAL

It is not applicable.

COMPETING INTERESTS

Authors have declared that no competing interests exist.

REFERENCES

- Alfalogy, E., Mahfouz, S., Elmedany, S., Hariri, N., & Fallatah, S. (2023). Chronic low back pain: Prevalence, impact on quality of life, and predictors of future disability. *Cureus*, *15*(9), e45760.
- Alfalogy, E., Mahfouz, S., Elmedany, S., Hariri, N., & Fallatah, S. (2023). Chronic low back pain: Prevalence, impact on quality of life, and predictors of future disability. *Cureus*, *15*(9), e45760.
- Badley, E. M., Rasooly, I., & Webster, G. K. (2010). Relative importance of musculoskeletal disorders as a cause of chronic health problems, disability, and health care utilization: Findings from the 1990 Ontario Health Survey. *Journal of Rheumatology*, 2, 505–514.
- Bai, K. S., Jayashree, D., & Uppu, S. D. C. (2024). A prospective comparative study on efficacy of oral vitamin D formulations in patients with chronic low back pain with vitamin D deficiency at a tertiary care hospital. *International Journal of Current Pharmaceutical Research*, 16(2), 65–68.
- Das, K. K., Chaturvedi, A., & Dhakad, R. K. S. (2023). Role of vitamin D supplementation in low back pain in young adults. *Journal of Cardiovascular Disease Research*, 14(1).
- Fatoye, F., Gebrye, T., & Odeyemi, I. (2019). Real-world incidence and prevalence of low back pain using routinely collected data. *Rheumatology International*, 39, 619–626.
- Ghai, B., Bansal, D., Kanukula, R., Gudala, K., Sachdeva, N., Dhatt, S. S., et al. (2017). Vitamin D supplementation in patients with chronic low back pain: An open-label, single arm clinical trial. *Pain Physician*, 20(1), E99–E105.
- Gokcek, E., & Kaydu, A. (2018). Assessment of relationship between vitamin D deficiency and pain severity in patients with low back pain: A retrospective, observational study. *Anesthesia Essays and Research*, *12*(3), 680–684.
- Goswami, R., Gupta, N., Ray, D., Singh, N., & Tomar, N. (2008). Pattern of 25-hydroxy vitamin D response at short (2 month) and

long (1 year) interval after 8 weeks of oral supplementation with cholecalciferol in Asian Indians with chronic hypovitaminosis D. *British Journal of Nutrition*, *100*(3), 526–529.

- Harinarayan, C. V., Srinivasa, P. M., Thennarasu,
 K., & Leena, A. (2023). Vitamin D supplementation therapy comparison of efficacy of three different protocols.
- Hayden, J. A., Ellis, J., Ogilvie, R., Malmivaara, A., & van Tulder, M. W. (2021). Exercise therapy for chronic low back pain. *Cochrane Database of Systematic Reviews*, 9(9), CD009790.
- Holick, M. F., Binkley, N. C., Bischoff-Ferrari, H. A., Gordon, C. M., Hanley, D. A., Heaney, R. P., et al. (2011). Evaluation, treatment, and prevention of vitamin D deficiency: An Endocrine Society clinical practice guideline. *Journal of Clinical Endocrinology & Metabolism*, *96*(7), 1911–1930.
- Jiang, Y., Wang, Y., Wang, R., Zhang, X., & Wang, X. (2022). Differences in pain, disability, and psychological function in low back pain patients with and without anxiety. *Frontiers in Physiology*, *13*, 906461.
- Kalra, S., Zargar, A. H., Unnikrishnan, A. G., Unnikrishnan, A. G., Dasgupta, A., Sahay, R., et al. (2023). Vitamin D in clinical practice: Current perspectives. *Indian Journal of Clinical Practice*, 33(11), 13–25.
- Khanna, M., Dahiya, A., Garg, A., Yadav, U., Sheoran, A., Dutta, M., et al. (2020). Estimation of vitamin D level in low backache cases and their outcome after treatment with vitamin D. *International Journal of Research in Orthopaedics*, 7, 120–124.
- Koley, S., & Sandhu, N. S. (2009). An association of body composition components with the menopausal status of patients with low back pain in Taran, Punjab, India. *Journal* of Life Sciences, 1, 129–132.
- Kuchay, M. S., Laway, B. A., Bashir, M. I., Wani, A. I., Misgar, R. A., & Shah, Z. A. (2015).
 Effect of vitamin D supplementation on glycemic parameters and progression of prediabetes to diabetes: A 1-year, openlabel randomized study. *Indian Journal of Endocrinology and Metabolism*, 19(3), 387–392.
- Lakkireddy, M., Karra, M. L., Patnala, C., Iyengar, R., Cherukuri, N., Hussain, K. S. A., et al. (2019). Efficiency of vitamin D supplementation in patients with mechanical low back ache. *Journal of*

Clinical Orthopaedics and Trauma, 10(6), 1101–1110.

- Marwaha, R. K., & Dabas, A. (2019). Bioavailability of nanoemulsion formulations vs conventional fat soluble preparations of cholecalciferol (D3) - An overview. *Journal of Clinical Orthopaedics and Trauma*, *10*(6), 1094–1096.
- Nandgaye, K. M., Samant, R. S., Kadam, S. B., & Palkar, P. J. (2023). Relative oral bioavailability of three formulations of vitamin D3: An open-label, three-treatment

study. International Journal of Basic & Clinical Pharmacology, 8(1), 138–142.

- Rebelos, E., Tentolouris, N., & Jude, E. (2023). The role of vitamin D in health and disease: A narrative review on the mechanisms linking vitamin D with disease and the effects of supplementation. *Drugs*, *83*(8), 665–685.
- V N., Nair, G. G., Jose, B. C., & Abraham, A. (2024). Study on vitamin D levels in 30 to 40-year-old females with low back pain. *Cureus*, *16*(2), e54238.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of the publisher and/or the editor(s). This publisher and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

© Copyright (2025): Author(s). The licensee is the journal publisher. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Peer-review history: The peer review history for this paper can be accessed here: https://www.sdiarticle5.com/review-history/128368